| Literature DB >> 18299957 |
Yuko Sugioka1, Kentaro Inui, Tatsuya Koike.
Abstract
Disease-modifying anti-rheumatic drugs (DMARDs) are typically used for the therapy of rheumatoid arthritis (RA), but most have some nephrotoxicity. In several clinical studies, etanercept had fewer adverse effects on renal function than other DMARDs. We report the case of a 64-year-old woman with RA and renal insufficiency on hemodialysis treated using etanercept therapy. This case suggests that etanercept therapy might be effective in the short term for such patients.Entities:
Mesh:
Substances:
Year: 2008 PMID: 18299957 DOI: 10.1007/s10165-008-0041-4
Source DB: PubMed Journal: Mod Rheumatol ISSN: 1439-7595 Impact factor: 3.023